Osimertinib-based adaptive treatment + Osimertinib 80 MG
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Conditions
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
Sep 23, 2025 → Jan 24, 2029
NCT ID
NCT07058519About Osimertinib-based adaptive treatment + Osimertinib 80 MG
Osimertinib-based adaptive treatment + Osimertinib 80 MG is a phase 2 stage product being developed by AstraZeneca for Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07058519. Target conditions include Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07058519 | Phase 2 | Recruiting |
Competing Products
20 competing products in Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)